Are you a Health Professional? Jump over to the doctors only platform. Click Here

Nonmalignant tumor cells predict lymphoma survival

In patients with follicular lymphoma, the molecular features of nonmalignant immune cells found in the tumor predict the length of survival, according to a report published in the November 18th issue of The New England Journal of Medicine.

A high degree of variability in survival is seen among patients with this malignancy — some live less than 1 year after diagnosis, while others live more than 20 years, according to the researchers.To identify predictors of survival, Dr. Louis M. Staudt, from the National Cancer Institute in Bethesda, Maryland, and colleagues analyzed gene-expression profiles of biopsy specimens.The study involved an analysis of 191 specimens obtained from patients with untreated disease. A training set of 95 specimens was used to identify expression patterns that correlated with survival.Two gene-expression signatures were discovered that allowed patients to be divided into four groups with widely different median survival periods (3.9, 10.8, 11.1, and 13.6 years), independently of standard prognostic variables.Further analysis revealed that these gene expression signatures did not come from malignant cells, but instead from nonmalignant immune cells found in the specimen.In a related editorial, Dr. Ralf Kuppers, from the University of Duisburg-Essen Medical School in Essen, Germany, comments that the findings “will certainly motivate further studies designed to improve our understanding of the way in which the cellular microenvironment influences the biology of follicular lymphoma.” Such investigations, “may also lead to new treatment options.”(Source: N Engl J Med 2004;351:2152-2153,2159-2169: Reuters Health: Oncolink: November 2004.)


Dates

Posted On: 18 November, 2004
Modified On: 16 January, 2014

Tags



Created by: myVMC